Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1463)	4/15/2003 6:09:41 PM
From: software salesperson	Read Replies (1) \| Respond to of 3044

erik, the call just ended. i always listen on the phone because of static and transmission problems. i'll be posting notes soon. sales

To: Icebrg who wrote (1463)	5/17/2003 9:56:00 PM
From: scaram(o)uche	Respond to of 3044

>> If however MLNM think it is worthwhile to mention a future conference presentation of the IBD-data, one (or at least I) cannot but assume, that the data are at least good enough to warrant a continuation into phase III. (Where DNA will meet the development costs). << messages.yahoo.com (of course, there's no need to point you to the post...... :-) 1. nice call, and 2. I worry about a lack of dose response when it's for something other than an arbitrary measure of "super drug" like CR on biopsy. I noticed it too, but..... decent sized trial, both 02 arms looking good relative to placebo for all criteria mentioned.